04405nam 2201177z- 450 991056646220332120231214133213.0(CKB)5680000000037759(oapen)https://directory.doabooks.org/handle/20.500.12854/81172(EXLCZ)99568000000003775920202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierOncolytic Virus ImmunotherapyBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (366 p.)3-0365-2549-1 3-0365-2548-3 Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.MedicinebicsscClinical & internal medicinebicssconcolytic virusesmelanomaimmunotherapycheckpoint inhibitorscombinatory therapyreovirusoncolytic virusadenovirusoncolyticvirotherapytargetingimmunogenic cell deathαvβ6 integrinoncolytic adenoviruscancer immunotherapymulti-stageimmunostimulatoryarmingHSV-1clinical trialsnewcastle disease virusNDVcancerimmune checkpoint inhibitorPD-1PD-L1CTLA-4type I interferonherpes simplex virusretargeted virustropism retargetingtumorcheckpoint inhibitorvaccinationantigen-agnostic vaccinationHER2parvovirustumor microenvironmentcombination therapyglioblastomapancreatic cancercolorectal cancermeasles virusvector engineeringimmune checkpoint blockadeantitumor immune responsedeliverygenetic modificationbiomarkerspersonalized oncolyticvirotherapyclass I HLAimmunosurveillanceimmunoeditingoncogenic signalingRASDNA methyltransferase inhibitor (DNMTi)viral mimicryepigenetic silencingadoptive T cell therapyCAR T cellpancreatic ductal adenocarcinomavesicular stomatitis virussmall moleculecancer immune therapycancer therapyMedicineClinical & internal medicineMarchini Antonioedt1309617Ilkow Carolina SedtMelcher AlanedtMarchini AntonioothIlkow Carolina SothMelcher AlanothBOOK9910566462203321Oncolytic Virus Immunotherapy3029458UNINA